Minnesota Statutes
Chapter 152 — Drugs; Controlled Substances
Section 152.37 — Financial Examinations; Pricing Reviews.

Subdivision 1. Financial records. A medical cannabis manufacturer shall maintain detailed financial records in a manner and format approved by the commissioner, and shall keep all records updated and accessible to the commissioner when requested.
Subd. 2. Certified annual audit. A medical cannabis manufacturer shall submit the results of an annual certified financial audit to the commissioner no later than May 1 of each year for the calendar year beginning January 2015. The annual audit shall be conducted by an independent certified public accountant and the costs of the audit are the responsibility of the medical cannabis manufacturer. Results of the audit shall be provided to the medical cannabis manufacturer and the commissioner. The commissioner may also require another audit of the medical cannabis manufacturer by a certified public accountant chosen by the commissioner with the costs of the audit paid by the medical cannabis manufacturer.
Subd. 3. Power to examine. (a) The commissioner or designee may examine the business affairs and conditions of any medical cannabis manufacturer, including but not limited to a review of the financing, budgets, revenues, sales, and pricing.
(b) An examination may cover the medical cannabis manufacturer's business affairs, practices, and conditions including but not limited to a review of the financing, budgets, revenues, sales, and pricing. The commissioner shall determine the nature and scope of each examination and in doing so shall take into account all available relevant factors concerning the financial and business affairs, practices, and conditions of the examinee. The costs incurred by the department in conducting an examination shall be paid for by the medical cannabis manufacturer.
(c) When making an examination under this section, the commissioner may retain attorneys, appraisers, independent economists, independent certified public accountants, or other professionals and specialists as designees. A certified public accountant retained by the commissioner may not be the same certified public accountant providing the certified annual audit in subdivision 2.
(d) The commissioner shall make a report of an examination conducted under this section and provide a copy to the medical cannabis manufacturer. The commissioner shall then post a copy of the report on the department's website. All working papers, recorded information, documents, and copies produced by, obtained by, or disclosed to the commissioner or any other person in the course of an examination, other than the information contained in any commissioner official report, made under this section are private data on individuals or nonpublic data, as defined in section 13.02.
2014 c 311 s 17; 2015 c 74 s 10

Structure Minnesota Statutes

Minnesota Statutes

Chapters 144 - 159 — Health

Chapter 152 — Drugs; Controlled Substances

Section 152.01 — Definitions.

Section 152.02 — Schedules Of Controlled Substances; Administration Of Chapter.

Section 152.021 — Controlled Substance Crime In The First Degree.

Section 152.022 — Controlled Substance Crime In The Second Degree.

Section 152.023 — Controlled Substance Crime In The Third Degree.

Section 152.024 — Controlled Substance Crime In The Fourth Degree.

Section 152.025 — Controlled Substance Crime In The Fifth Degree.

Section 152.026 — Mandatory Sentences.

Section 152.0261 — Importing Controlled Substances Across State Borders.

Section 152.0262 — Possession Of Substances With Intent To Manufacture Methamphetamine Crime.

Section 152.027 — Other Controlled Substance Offenses.

Section 152.0271 — Notice Of Drug Convictions; Driver's License Revocation.

Section 152.0273 — Synthetic Drug Sales; Mandatory Restitution.

Section 152.0275 — Certain Controlled Substance Offenses; Restitution; Prohibitions On Property Use; Notice Provisions.

Section 152.028 — Permissive Inference Of Knowing Possession.

Section 152.029 — Public Information; School Zones, Park Zones, Public Housing Zones, And Drug Treatment Facilities.

Section 152.092 — Possession Of Drug Paraphernalia Prohibited.

Section 152.093 — Manufacture Or Delivery Of Drug Paraphernalia Prohibited.

Section 152.094 — Delivery Of Drug Paraphernalia To A Minor Prohibited.

Section 152.095 — Advertisement Of Drug Paraphernalia Prohibited.

Section 152.096 — Conspiracies Prohibited.

Section 152.097 — Simulated Controlled Substances.

Section 152.0971 — Terms.

Section 152.0972 — Precursors Of Controlled Substances.

Section 152.0973 — Report Of Transaction.

Section 152.0974 — Exceptions.

Section 152.10 — Sales, Persons Eligible.

Section 152.101 — Manufacturers, Records.

Section 152.105 — Disposal.

Section 152.11 — Prescriptions.

Section 152.12 — Health Care Providers May Prescribe.

Section 152.125 — Intractable Pain.

Section 152.126 — Prescription Monitoring Program.

Section 152.13 — Duties Of State Board Of Pharmacy.

Section 152.135 — Restrictions On Sales, Marketing, And Possession Of Ephedrine.

Section 152.136 — Anhydrous Ammonia; Prohibited Conduct; Criminal Penalties; Civil Liability.

Section 152.137 — Methamphetamine-related Crimes Involving Children And Vulnerable Adults.

Section 152.152 — Stayed Sentence Limited.

Section 152.18 — Discharge And Dismissal.

Section 152.20 — Penalties Under Other Laws.

Section 152.205 — Local Regulations.

Section 152.21 — Thc Therapeutic Research Act.

Section 152.22 — Definitions.

Section 152.23 — Limitations.

Section 152.24 — Federally Approved Clinical Trials.

Section 152.25 — Commissioner Duties.

Section 152.26 — Rulemaking.

Section 152.261 — Rules; Adverse Incidents.

Section 152.27 — Patient Registry Program Established.

Section 152.28 — Health Care Practitioner Duties.

Section 152.29 — Manufacturer Of Medical Cannabis Duties.

Section 152.30 — Patient Duties.

Section 152.31 — Data Practices.

Section 152.32 — Protections For Registry Program Participation.

Section 152.33 — Violations.

Section 152.34 — Health Care Facilities.

Section 152.35 — Fees; Deposit Of Revenue.

Section 152.36 — Impact Assessment Of Medical Cannabis Therapeutic Research.

Section 152.37 — Financial Examinations; Pricing Reviews.